加载中
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
收盘时
US$1.28
+US$0.01 · +0.79%
盘后
US$1.2806
+US$0.0006 · +0.05%
10月12日 16:20 ET
盘中时间采用ET。市场数据可能有所延迟。
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
日内区间
当前US$1.28
52周区间
当前US$1.28
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
49
合理估值
情绪
54
多空交织
风险
66
高风险
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
日内区间
当前US$1.28
52周区间
当前US$1.28
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 18.35亿 USD | 540.38万 USD | 604.36万 USD | 475.43万 USD | 203.02万 USD |
| 销售、一般及管理费用 | 62.57亿 USD | 869.93万 USD | 853.42万 USD | 733.85万 USD | 1078.4万 USD |
| 营业费用 | 809.2万 USD | 1410.31万 USD | 1457.78万 USD | 1209.28万 USD | 1281.42万 USD |
| 利息收入 | 12.54万 USD | — | — | — | — |
| 折旧和摊销 | — | 1412.32万 USD | — | — | — |
| 营业利润 | −809.2万 USD | −1410.31万 USD | −1457.78万 USD | −1209.28万 USD | −1281.42万 USD |
| 净利润 | −796.65万 USD | −1410.31万 USD | −1457.78万 USD | −1209.28万 USD | −1274.77万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年8月5日 | 1:20 | — | — |
已生效 2025年8月5日
1:20
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
